# Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

> **NCT03468296** · PHASE4 · UNKNOWN · sponsor: **Tennessee Retina** · enrollment: 22 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Intravitreal Aflibercept Injection 2mg

## Key facts

- **NCT ID:** NCT03468296
- **Lead sponsor:** Tennessee Retina
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04
- **Primary completion:** 2018-10
- **Final completion:** 2019-07
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2018-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468296, "Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03468296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*